Ireland· IE-PA-EU/1/18/1315/003-004
Mektovi 45 mg Film-coated tablet
A binimetinib product containing binimetinib, registered in Ireland by Pierre Fabre Medicament. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Binimetinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EE03 (binimetinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Binimetinib · ATC L01EE03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of binimetinib costs, country by country.
Normalised to the WHO defined daily dose (90 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Binimetinib · price per daily dose (90 mg)
USD · FX 28 Sept 2026
- CH Switzerland$202.25
The record
At a glance
HPRA (Ireland)- Active substance
- Binimetinib
- Manufacturer
- Pierre Fabre Medicament
- Country
- Ireland (IE)
- ATC code
- L01EE03
- ATC class
- Binimetinib
- Defined daily dose
- 90 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1315/003-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
211 interactions on record for binimetinib.
Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Binimetinib · interactions on record
211 records
- 31 severe
- 180 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- TipranavirJ05AE09severe
- DasatinibL01EA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Binimetinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandMektovi 45 mg, FilmtablettenPierre Fabre Pharma SA
- CzechiaMEKTOVIPIERRE FABRE MEDICAMENT, Lavaur
- FinlandMektoviPierre Fabre Medicament
- FranceMEKTOVI 45 mg, comprimé pelliculéPIERRE FABRE MEDICAMENT
- IcelandMektoviPierre Fabre Medicament
- NetherlandsMektovi 45 mg, filmomhulde tablettenPierre Fabre Medicament
- NorwayMektoviPierre Fabre Medicament
- PolandMektoviPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Mektovi
- Liechtenstein · Mektovi
- Norway · Mektovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffb762a3-5c4b-4f34-9708-ee1f80149e98 GET /v1/drugs/ffb762a3-5c4b-4f34-9708-ee1f80149e98?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EE03"
],
"strength": null,
"pa_number": "EU/1/18/1315/003-004",
"substances": [
"Binimetinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "17/06/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about binimetinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.